Original Article

You have full text access to this OnlineOpen article

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD†

  1. Paul Angulo1,‡,*,
  2. Jason M. Hui2,
  3. Giulio Marchesini3,
  4. Ellisabetta Bugianesi4,
  5. Jacob George2,
  6. Geoffrey C. Farrell2,
  7. Felicity Enders5,
  8. Sushma Saksena6,
  9. Alastair D. Burt6,
  10. John P. Bida5,
  11. Keith Lindor1,
  12. Schuyler O. Sanderson7,
  13. Marco Lenzi8,
  14. Leon A. Adams1,
  15. James Kench9,
  16. Terry M. Therneau5,
  17. Christopher P. Day6

Article first published online: 28 MAR 2007

DOI: 10.1002/hep.21496

Issue

Hepatology

Hepatology

Volume 45, Issue 4, pages 846–854, April 2007

Additional Information

How to Cite

Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., Lindor, K., Sanderson, S. O., Lenzi, M., Adams, L. A., Kench, J., Therneau, T. M. and Day, C. P. (2007), The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 45: 846–854. doi: 10.1002/hep.21496

Author Information

  1. 1

    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN

  2. 2

    Storr Liver Unit, Westmead Hospital and Westmead Millennium Institute, University of Sydney, Australia

  3. 3

    Department of Medicine, Alma Mater Studiorum University, Bologna, Italy

  4. 4

    Division of Gastroenterology, University of Turin, Ospedale San Giovanni Battista, Turin, Italy

  5. 5

    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN

  6. 6

    School of Clinical Medical Sciences, University of Newcastle and Freeman Hospital, Newcastle upon Tyne, UK

  7. 7

    Division of Anatomic Pathology, Mayo Clinic College of Medicine, Rochester, MN

  8. 8

    Pathology, Alma Mater Studiorum University, Bologna, Italy

  9. 9

    Department of Anatomical Pathology, Westmead Hospital and Westmead Millennium Institute, University of Sydney, Australia

  1. ‡

    fax: 507-266-4531

*Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905

  1. †

    Potential conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 28 MAR 2007
  2. Article first published online: 28 MAR 2007
  3. Manuscript Accepted: 2 NOV 2006
  4. Manuscript Received: 19 MAY 2006

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (176K)

References

  • 1
    Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. HEPATOLOGY 2004; 40: 1387–1395.
    Direct Link:
  • 2
    Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. HEPATOLOGY 2005; 42: 44–52.
    Direct Link:
  • 3
    Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005; 43: 508–514.
  • 4
    Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; 27: 142–149.
  • 5
    Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. HEPATOLOGY 1999; 29: 664–669.
    Direct Link:
  • 6
    Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carrucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134–140.
  • 7
    Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005; 129: 113–121.
  • 8
    Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. HEPATOLOGY 2006; 43: 682–689.
    Direct Link:
  • 9
    Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. HEPATOLOGY 1995; 22: 1714–1719.
    Direct Link:
  • 10
    Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sorensen TIA, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53: 750–755.
  • 11
    Mendes FD, Suzuki A, Angulo P. Prevalence and indicators of portal hypertension in nonalcoholic fatty liver disease. Gastroenterology 2004; 126: A759.
  • 12
    Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Non alcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–1419.
  • 13
    Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. HEPATOLOGY 2006; 44: 865–873.
    Direct Link:
  • 14
    Hui JM, Kench JG, Chitturi S, Sud A, Farrell GC, Byth K, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. HEPATOLOGY 2003; 38: 420–427.
    Direct Link:
  • 15
    Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. HEPATOLOGY 1999; 30: 1356–1362.
    Direct Link:
  • 16
    Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology. 2000; 118: 1117–1123.
  • 17
    Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91–100.
  • 18
    Shimada M, Hashimoto E, Kaneda H, Noguchi S, Hayashi N. Nonalcoholic steatohepatitis: risk factors for liver fibrosis. J Hepatol 2002; 24: 429–438.
  • 19
    Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704–1713.
  • 20
    Sukugagwa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005; 11: 255–259.
  • 21
    Johansen JS, Christoffersen P, Moller S, Price PA, Henriksen JH, Garbarsch C, et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000; 32: 911–920.
  • 22
    Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology 2006; 6: 6.
  • 23
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostatic model assessment: insulin resistance and beta-cell function from fasting glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
  • 24
    Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. HEPATOLOGY 2003; 38: 518–526.
    Direct Link:
  • 25
    Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005; 41: 1313–1321.
    Direct Link:
  • 26
    Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. HEPATOLOGY 2005; 41: 48–54.
    Direct Link:
  • 27
    Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343–350.
  • 28
    Foucher J, Castera L, Bernard PH, Adhoute X, Laharie D, Bertet J, et al. Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol 2006; 18: 411–412.
  • 29
    Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898–1906.
  • 30
    Rousselet MC, Michalak S, Dupre F, Croue A, Bedosa P, Saint-Andre JP, et al. Source of variability in histological scoring of chronic viral hepatitis. HEPATOLOGY 2005; 41: 257–264.
    Direct Link:
View Full Article (HTML) Get PDF (176K)